Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion

Gabriel Coscas, Albert Augustin, Francesco Bandello, Marc D. De Smet, Paolo Lanzetta, Giovanni Staurenghi, Maria Cristina Parravano, Patricia Udaondo, Elad Moisseiev, Gisele Soubrane, Yossi Yatziv, Anat Loewenstein

Research output: Contribution to journalArticlepeer-review


Purpose: To review the current practice of retreatment with Ozurdex injections in patients with macu-lar edema (ME) secondary to retinal vein occlusion (RVO), and to recommend simple guidelines for Ozurdex reinjection in management of RVO. Methods: This was a multicenter retrospective study of patients who received more than 2 Ozurdex injections for the treatment of ME in RVO. Recorded parameters included percent of patients with a 15-letter gain, visual acuity (VA) improvement from baseline, change in central macular thickness (CMT), time to reinjection, and occurrence of any complications. Results: A total of 128 patients were included, 58 (45.3%) with central RVO (CRVO) and 70 (54.7%) with branch RVO (BRVO). Mean interval for Ozurdex reinjection was 5.9 months following the first injection and 8.7 months following the second. A >15-letter gain in VA was observed in 34 (48.8%) patients with CRVO and 16 (28%) patients with BRVO. Mean overall VA improvement at month 6 did not show significance (p>0.05); however, a significantly better mean VA improvement was seen in treatment-naïve eyes (p

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalEuropean Journal of Ophthalmology
Issue number1
Publication statusPublished - Oct 14 2013


  • Dexamethasone implant
  • Macular edema
  • Ozurdex
  • Retinal vein occlusion
  • Retreatment

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion'. Together they form a unique fingerprint.

Cite this